The trial is expected to generate significant clinical data by late summer 2026. Allarity plans to pursue multiple advantaged ...

Therapeutics announced that the first patient has been enrolled in its new Phase 2 clinical trial protocol of stenoparib for the ...

June 4, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a ...

Tarpon Springs, Florida Wednesday, June 4, 2025, 12:00 Hrs [IST] ...

Allarity Therapeutics ( ($ALLR) ) has shared an update. On June 2, 2025, Allarity Therapeutics announced the enrollment of the first patient in ...

Stenoparib is an orally available small-molecule drug that inhibits both PARP1/2 and tankyrase1/2, targeting DNA repair and the WNT signaling pathway—key drivers in treatment resistance and ...

June 2, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a ...

TARPON SPRINGS, Fla., June 2, 2025 -- Allarity Therapeutics, Inc. (ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT ...